A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient

NCT ID: NCT05493631

Last Updated: 2025-11-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-08-24
• Study Completion Date: 2024-12-11

Brief Summary

The purpose of this study is to assess the safety and tolerability, pharmacokinetics and pharmacodynamics of subcutaneous MG1113 in the multiple ascending dose study in patients with severe hemophilia.

Detailed Description

This is a repeat-dose study that assign 5 subjects in each cohort to explore the safety, tolerability, PK, and PD of the study drug by sequentially increasing the study drug.

The route of administration is subcutaneous (SC) injection. Dose escalation will be decided after checking the safety and tolerability at the previous dose to the extent not exceeding the criteria for discontinuation of dose escalation. The dose escalation will be decided by the Steering Committee and Data and Safety Monitoring Boards (DSMB) in the evaluation of the safety and tolerability data obtained from each cohort after repeated administration of MG1113.

The subjects will be treated with 2.0 mg/kg once weekly for 8 weeks in cohort 1. Visit window of ±1 day (calculated from Day1) are allowed for the dosing schedule after first IP administration (Day 1). But next scheduled IP administration must be kept in mind to ensure subjects will not have more than 8 days in between IP dosing interval.

The next dose level (Dose A and B) will be determined based on the safety, PK, and PD data obtained from previous dose level. If a criterion of discontinuation of dose escalation is fulfilled, discussion about dose escalation is available for next cohort. The dose selection and escalation will be finally determined from the Steering Committee and DSMB. The safety, tolerability, PK, and PD data obtained from all subjects up to Cohort 3 will be evaluated by the Steering Committee and Data and Safety Monitoring Boards (DSMB).

Conditions

Hemophilia

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cohort 1 (2.0 mg/kg, once weekly)

• Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody
• Each vial contains 1mL of study drug
• The subjects will be treated with 2.0 mg/kg once weekly in cohort 1.

Group Type: ACTIVE_COMPARATOR

MG1113

Intervention Type: BIOLOGICAL

MG1113 subcutaneous (SC) injection

Cohort 2 (A mg/kg, once weekly)

• Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody
• Each vial contains 1mL of study drug
• The subjects will be treated with A mg/kg once weekly in cohort 2.
• The Dose A mg/kg will be determined based on the safety, PK, and PD data obtained from previous dose level (cohort 1).

Group Type: ACTIVE_COMPARATOR

MG1113

Intervention Type: BIOLOGICAL

MG1113 subcutaneous (SC) injection

Cohort 3 (B mg/kg, once weekly)

• Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody
• Each vial contains 1mL of study drug
• The subjects will be treated with B mg/kg once weekly in cohort 3.
• The Dose B mg/kg will be determined based on the safety, PK, and PD data obtained from previous dose level (cohort 2).

Group Type: ACTIVE_COMPARATOR

MG1113

Intervention Type: BIOLOGICAL

MG1113 subcutaneous (SC) injection

Interventions

MG1113

MG1113 subcutaneous (SC) injection

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Male severe hemophilia A or B patients (FVIII or FIX activity <1%) aged 19-60 years (both inclusive) at screening

• Patients without inhibitors against FVIII or FIX (having difficulty in their Self-injection of current standard treatment regimen) OR
• Patients with inhibitors who has a positive inhibitor result of confirmed human factor VIII or IX with an inhibitor titer(≥ 0.6 BU) and failed after ITI treatment or not undergoing ITI

2. ≥50 kg in weight with calculated BMI between 18.5 and 29.9 kg/m^2 (BMI = (Weight [kg])/(height [m])^2)

3. Documentation of ≥4 bleeding episodes (any type or location of bleeds, treated or not) within 6 months prior to screening

4. Agree to use medically acceptable adequate dual contraceptive methods (condom, vasectomy, spermicide, oral contraceptives, intrauterine device, and complete sexual abstinence, etc.) and not to donate sperm until 60 days after administration of the investigational product

5. Voluntarily decided to participate in the study and provided written consent to follow precautions after receiving a detailed explanation on this study and fully understanding the information

Exclusion Criteria

1. Congenital or acquired anticoagulant disorders other than hemophilia A or B, or conditions of other diseases that increase the risk of bleeding or thrombus (e.g., autoimmune disease)

2. Be at risk of venous thromboembolism or thrombotic microangiopathy per investigator's judgment or have related medical history or family history

3. Be at risk of cardia and/or coronary disease per investigator's judgment or have related medical history or family history

4. Risk factors for venous or arterial disease (e.g., uncontrolled hypertension, uncontrolled diabetes)

5. Any of the following results from laboratory tests:

• AST(sGOT) or AST(sGPT) > 3 x UNL
• Total bilirubin > 2 mg/mL
• Hb < 9.0 g/dL
• Absolute Neutrophil Count < 1500 /μL
• Platelet count < 10^5 /μL
• Have hepatitis B (HBs Ag positive) or C (anti-HCV positive), or have HIV positive test result If the anti-HCV antibody test is positive, the positive hepatitis virus result must be confirmed by a quantitative HCV RNA test
• Serum Creatinine > 1.5 x Upper limit of normal (ULN)

6. Known or suspected hypersensitivity to the IP or its components

7. Treatment history due to symptoms of fever within 28 days of IP administration or any surgery planned during the study period

8. Clinically significant active chronic disease

9. Subjects who refuse the following wash-out times of Factor VIII, Factor IX, and bypassing agent from the time of first IP administration (Factor VIII: 72 hrs, Factor IX: 96 hrs, Bypassing agent e.g., rFVIIa or aPCC: 96 hrs)

10. Received immune tolerance induction within 30 days prior to administration of the investigational product

11. Received emicizumab within 30 days prior to administration of the investigational product

12. Currently using systemic immunomodulator treatment (e.g., Corticosteroid*, IVIG, interferon or rituximab)

*High-dose corticosteroids (it is allowed to administer corticosteroid equivalent to up to 20mg/kg daily based on Prednisolone, but if a dose of more is continuously administered in excess of 14 days, it is considered as high dose, such case is excluded from this study. However, inhaled, intranasal, and topical administration of corticosteroids is allowed irrespective of the dose.)

13. Participated in another clinical trial within 30 days of investigational product administration

14. Determined to be ineligible to participate in the study per investigator's judgment due to other reasons including the laboratory test results

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

GC Biopharma Corp

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Eun-Jin Choi

Role: PRINCIPAL_INVESTIGATOR

Daegu Catholic University Medical Center

Locations

GC Biopharma Corp.

Yongin-si, Gyeonggi-do, South Korea

Countries

South Korea

Other Identifiers

MG1113_HP_P0101

Identifier Type: -

Identifier Source: org_study_id